Kärt Tomberg

Dr. Kärt Tomberg is the CEO and co-founder of ExpressionEdits, a Cambridge-based company rebuilding synthetic genes to look more like nature. She invented the intronization approach that led to the company's formation and now leads its platform and drug development strategy. Kärt trained as a human geneticist. She earned her bachelor's and master's degrees at the University of Tartu in her native Estonia, then joined David Ginsburg's lab at the University of Michigan as a Fulbright Fellow for her PhD. In 2017 she moved to Allan Bradley's lab at the University of Cambridge as a Sir Henry Wellcome Postdoctoral Fellow, where the founding science took shape. Over the past five years she has grown ExpressionEdits to a team of 17, secured multiple financing rounds, and established partnerships with major pharma. She remains focused on turning better gene design into better medicines.